Sanofi SA (ADR) (NYSE:SNY) has been upgraded to Buy in a statement by Natixis earlier today.
- Updated: February 11, 2017
Natixis has upgraded Sanofi SA (ADR) (NYSE:SNY) to Buy in a statement released on 02/09/2017.
Boasting a price of $41.21, Sanofi SA (ADR) (NYSE:SNY) traded -0.30% lower on the day. With the last stock price close up 7.13% from the two hundred day average, compared with the S&P 500 Index which has increased 0.06% over the date range. Sanofi SA (ADR) has recorded a 50-day average of $40.57 and a two hundred day average of $39.74. Volume of trade was down over the average, with 1,159,991 shares of SNY changing hands under the typical 1,940,120
With a total market value of $0, Sanofi SA (ADR) has price-earnings ratio of 24.32 with a one year low of $36.81 and a one year high of $44.50 .
A total of 3 equity analysts have released a ratings update on SNY. One equity analyst rating the company a strong buy, zero equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $52.00.
Brief Synopsis About Sanofi SA (ADR) (NYSE:SNY)
Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation. Its pharmaceuticals portfolio consists of products and a range of prescription medicines, generic medicines and consumer health products. The Vaccines segment is dedicated to vaccines, including research, development, production and marketing. The Animal Health segment includes the research, development, production and marketing activities of Merial, which offers a range of medicines and vaccines for a range of animal species. It operates in the Other segment, which includes the effects of retained commitments. It operates through Regeneron Pharmaceuticals Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.